Vol. 5 No. 11 (2025)
Reimbursement Reviews

Tofacitinib

decorative image of the issue cover

Published November 10, 2025

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses Tofacitinib 5 mg and 10 mg oral tablets.
  • Indication under consideration for reimbursement: For the treatment of active pJIA (RF-positive or RF-negative polyarthritis, extended oligoarthritis, and systemic JIA without active systemic manifestations), psoriatic arthritis, and enthesitis-related arthritis in children who have responded inadequately or are intolerant to TNF inhibitors or when use of those therapies is inadvisable.